BridgeBio PharmaFRA:2CL +2.55%67 Days Inventory is 272.65 as of Mar. 2026, which is 41% below its 10-year median of 465.84. GuruFocus rates FRA:2CL with a GF Score™ of 67/100 and a GF Value™ of €122.60 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 638 Biotechnology companies, BridgeBio Pharma ranks worse than 64.89% on this metric.
The historical rank and industry rank for BridgeBio Pharma's Days Inventory or its related term are showing as below:
FRA:2CL'
s Days Inventory Range Over the Past 10 Years
Min: 275.06 Med: 465.84 Max: 465.84
Current: 275.06
During the past 9 years, BridgeBio Pharma's highest Days Inventory was 465.84. The lowest was 275.06. And the median was 465.84.
FRA:2CL's Days Inventory is ranked worse than 64.89% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs FRA:2CL: 275.06
BridgeBio Pharma's Days Inventory
increased
from Mar. 2025 (136.65) to Mar. 2026 (272.65).
It might indicate that BridgeBio Pharma's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BridgeBio Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BridgeBio Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.15.
BridgeBio Pharma (FRA:2CL) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BridgeBio Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BridgeBio Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BridgeBio Pharma Days Inventory Related Terms
BridgeBio Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs EXEL, IONS, JAZZ: Days Inventory Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Days Inventory of 272.65 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BridgeBio Pharma and its competitors. This is 41% below median its historical median of 465.84. Over the past decade, BridgeBio Pharma's Days Inventory has ranged from 275.06 to 465.84. According to the industry distribution chart, BridgeBio Pharma ranks #414 out of 638 companies in the Biotechnology industry, placing it in the top 64.9%.
Is BridgeBio Pharma's Days Inventory too high?
BridgeBio Pharma's current Days Inventory of 272.65 is 41% below median its 10-year median of 465.84. Over the past 10 years, this metric has ranged from a low of 275.06 to a high of 465.84. The Biotechnology industry median Days Inventory is 183.88. BridgeBio Pharma's value of 272.65 is 48.3% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #414 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Days Inventory compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #414 out of 638 companies for Days Inventory. This places BridgeBio Pharma in the lower half of its industry. The industry median Days Inventory is 183.88. BridgeBio Pharma's value of 272.65 is 48.3% above this benchmark. Historically, BridgeBio Pharma's own Days Inventory has ranged from 275.06 to 465.84 over the past decade. While the company's 10-year median is 465.84 vs. the industry median of 183.88, BridgeBio Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Days Inventory of 272.65 is 48.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Days Inventory is 272.65, which is 41% below median its own 10-year median of 465.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.60, compared to a current price of €61.46 — trading 49.9% below its estimated fair value. The current Days Inventory is 272.65, which is 41% below median its 10-year median of 465.84 and 48.3% above the Biotechnology industry median of 183.88. BridgeBio Pharma's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Days Inventory is 272.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €61.46 is trading 49.9% below its estimated GF Value™ of €122.60.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Days Inventory: 272.65 (41% below median its 10-year median of 465.84)
GF Value™: €122.60 vs. price of €61.46 (49.9% below fair value)
Industry Position: 48.3% above the Biotechnology median (#414 of 638)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
67GF Score
Get the complete analysis for FRA:2CL
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
